Saccade Diagnostics Limited

Biomarkers have the potential to revolutionize the diagnosis and management of psychiatric disorders which affects 1 in 5 of us during our lifetime. The present symptom based diagnoses are unreliable with more than 50% of cases misdiagnosed at first presentation leading to suboptimal, inappropriate or even dangerous treatments. We have developed SaccScan – a Point-of-Care tool which has been demonstrated to detect schizophrenia and related illnesses with better than 95% accuracy. Early economic modelling showed that early detection of schizophrenia using SaccScan could produce savings of £33,474 per patient in the case of suspected schizophrenia alone.